Positioning Dipeptidyl Peptidase-1 Inhibitors in Bronchiectasis: No Drug Is an Island

Key Points

• Dipeptidyl peptidase-1 inhibitors may influence treatment outcomes in bronchiectasis, as explored in this analysis.
• The study discusses treatment complexities, emphasizing the interdependence of various drugs in managing bronchiectasis.
• Observational analysis of treatment impacts suggests that no drug operates in isolation, affecting bronchiectasis outcomes.
• Understanding the role of dipeptidyl peptidase-1 inhibitors may inform future treatment strategies for bronchiectasis.